Your browser doesn't support javascript.
loading
Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study.
Ascierto, Paolo A; Cioli, Eleonora; Chiarion-Sileni, Vanna; Quaglino, Pietro; Spagnolo, Francesco; Guidoboni, Massimo; Del Vecchio, Michele; Peris, Ketty; Queirolo, Paola; Fioretto, Luisa; Caracò, Corrado; Paone, Miriam; Sorrentino, Antonio; Capone, Mariaelena; Giannarelli, Diana; Ferrara, Gerardo; Massi, Daniela; Trojaniello, Claudia.
Affiliation
  • Ascierto PA; Department of Melanoma, Cancer Immunotherapy and Development Therapeutics. Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale" Napoli, Naples, Italy.
  • Cioli E; Department of Melanoma, Cancer Immunotherapy and Development Therapeutics. Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale" Napoli, Naples, Italy.
  • Chiarion-Sileni V; Melanoma Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.
  • Quaglino P; Department of Medical Sciences, Dermatologic Clinic, University of Turin, Turin, Italy.
  • Spagnolo F; Skin Cancer Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
  • Guidoboni M; Immunotherapy and Cell Therapy Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
  • Del Vecchio M; Unit of Melanoma Medical Oncology, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Peris K; Catholic University of the Sacred Heart and Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome, Italy.
  • Queirolo P; Skin Cancer Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
  • Fioretto L; Division of Melanoma Sarcoma and Rare Tumors, IEO European Institute of Oncology IRCCS Milan, Milan, Italy.
  • Caracò C; Medical Oncology Unit, Department of Oncology, Santa Maria Annunziata Hospital, Azienda USL Toscana Centro, Florence, Italy.
  • Paone M; Melanoma and Skin Cancers Surgery Unit, Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", Napoli, Italy.
  • Sorrentino A; Department of Melanoma, Cancer Immunotherapy and Development Therapeutics. Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale" Napoli, Naples, Italy.
  • Capone M; Department of Melanoma, Cancer Immunotherapy and Development Therapeutics. Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale" Napoli, Naples, Italy.
  • Giannarelli D; Department of Melanoma, Cancer Immunotherapy and Development Therapeutics. Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale" Napoli, Naples, Italy.
  • Ferrara G; Fondazione Policlinico Universitario A. Gemelli, IRCCS - Facility of Epidemiology & Biostatistics, Rome, Italy.
  • Massi D; Department of Pathology and Cytopathology, Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", Napoli, Italy.
  • Trojaniello C; Section of Pathology, Department of Health Sciences, University of Florence, Florence, Italy.
Front Oncol ; 13: 1107307, 2023.
Article in En | MEDLINE | ID: mdl-36845751
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials / Etiology_studies / Guideline / Qualitative_research / Risk_factors_studies Language: En Journal: Front Oncol Year: 2023 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials / Etiology_studies / Guideline / Qualitative_research / Risk_factors_studies Language: En Journal: Front Oncol Year: 2023 Document type: Article